PDCD1 and non-small cell lung carcinoma: Based on this, we suggest that the value of delta‐He is a good predictive and prognostic marker in patients with NSCLC treated with PD‐1/PD‐L1 inhibitors, excluding other factors that may affect treatment, such as driver mutation or radiotherapy.